Information Provided By:
Fly News Breaks for February 13, 2017
SRPT
Feb 13, 2017 | 13:56 EDT
Credit Suisse analyst Alethia Young said weakness in shares of Sarepta may be due to confusion around the impact of Deflazacort, Marathon's recently approved steroid for use by Duchenne muscular dystrophy patients. However, she notes that all DMD patients are typically on steroids, this drug has been available outside the U.S. and used off label in the U.S. previously, that it is not a competitor to EXONDYS 51 and does not affect the treatment paradigm. Young has an Outperform rating and $66 price target on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT